Comparative Pharmacology
Head-to-head clinical analysis: PRAZEPAM versus VALIUM.
Head-to-head clinical analysis: PRAZEPAM versus VALIUM.
PRAZEPAM vs VALIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prazepam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) activity at GABA-A receptors, leading to increased chloride ion influx, neuronal hyperpolarization, and central nervous system depression.
Benzodiazepine that enhances the effect of GABA at GABA-A receptors, increasing chloride ion conductance and producing neuronal hyperpolarization.
10-30 mg orally 3-4 times daily; maximum daily dose 60 mg.
Oral: 2-10 mg 2-4 times daily. IV/IM: 5-10 mg, repeat in 3-4 hours if needed; max 30 mg in 8 hours.
None Documented
None Documented
Terminal elimination half-life: 36-200 hours (mean ~75 hours). Long half-life leads to accumulation with repeated dosing and prolonged sedation, especially in elderly or hepatic impairment.
Clinical Note
moderatePrazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prazepam is combined with Fluticasone propionate."
Clinical Note
moderatePrazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Prazepam."
Clinical Note
moderatePrazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Prazepam."
Clinical Note
moderatePrazepam + Cyclosporine
Terminal elimination half-life of diazepam: 20–50 hours; active metabolite desmethyldiazepam half-life: 36–200 hours (accumulates with chronic dosing, prolonging clinical effects).
Primarily renal (as conjugated metabolites, mainly oxazepam glucuronide): ~95%; fecal: ~5%.
Renal: <1% unchanged; hepatic metabolism to active metabolites (desmethyldiazepam, temazepam, oxazepam); metabolites excreted renally as glucuronides. Fecal: minor.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Prazepam."